Show simple item record

dc.contributor.authorABOU JOKH CASAS, ESTEPHANY 
dc.contributor.authorPubul Nuñez, Virginia 
dc.contributor.authorAnido Herranz, Urbano 
dc.contributor.authorMallón Araujo, María del Carmen
dc.contributor.authorDel Pombo Pasín, Maria Carmen
dc.contributor.authorGarrido Pumar, Miguel 
dc.contributor.authorCabezas Agrícola, José Manuel
dc.contributor.authorCameselle Teijeiro, Jose Manuel 
dc.contributor.authorHilal, A.
dc.contributor.authorRuibal Morell, Alvaro 
dc.date.accessioned2022-04-12T11:37:28Z
dc.date.available2022-04-12T11:37:28Z
dc.date.issued2020
dc.identifier.issn1007-9327
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/32308351es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/16456
dc.description.abstractBACKGROUND: (177)Lu peptide receptor radionuclide therapy (PRRT) is a recently approved therapy in Spain that has been demonstrated to be a well-tolerated therapy for positive somatostatin receptor advanced gastroenteropancreatic neuroendocrine tumors. AIM: To determine the impact of PRRT on quality of life, radiologic and metabolic response, overall survival, prognostic factors and toxicity. METHODS: Thirty-six patients treated with (177)Lu-PRRT from 2016 to 2019 were included. The most frequent location of the primary tumor was the gastrointestinal tract (52.8%), pancreas (27.8%), and nongastropancreatic neuroendocrine tumor (11.1%). The liver was the most common site of metastasis (91.7%), followed by distant nodes (50.0%), bone (27.8%), peritoneum (25.0%) and lung (11.1%). Toxicity was evaluated after the administration of each dose. Treatment efficacy was evaluated by two parameters: stable disease and disease progression in response evaluation criteria in solid tumors 1.1 criterion and prognostic factors were tested. RESULTS: From 36 patients, 55.6% were men, with a median age of 61.1 +/- 11.8 years. Regarding previous treatments, 55.6% of patients underwent surgery of the primary tumor, 100% of patients were treated with long-acting somatostatin analogues, 66.7% of patients were treated with everolimus, 27.8% of patients were treated with tyrosine kinase inhibitor, and 27.8% of patients were treated with interferon. One patient received radioembolization, three patients received chemoembolization, six patients received chemotherapy. Hematological toxicity was registered in 14 patients (G1-G2: 55.5% and G3: 3.1%). Other events presented were intestinal suboclusion in 4 cases, cholestasis in 2 cases and carcinoid crisis in 1 case. The median follow-up time was 3 years. Currently, 24 patients completed treatment. Nineteen are alive with stable disease, two have disease progression, eight have died, and nine are still receiving treatment. The median overall survival was 12.5 mo (95% confidence interval range: 9.8-15.2), being inversely proportional to toxicity in previous treatments (P < 0.02), tumor grade (P < 0.01) and the presence of bone lesions (P = 0.009) and directly proportional with matching lesion findings between Octreoscan and computed tomography pre-PRRT (P < 0.01), , primary tumor surgery (P = 0.03) and metastasis surgery (P = 0.045). In a multivariate Cox regression analysis, a high Ki67 index (P = 0.003), a mismatch in the lesion findings between Octreoscan and computed tomography pre-PRRT (P < 0.01) and a preceding toxicity in previous treatments (P < 0.05) were risk factors to overall survival. CONCLUSION: Overall survival was inversely proportional to previous toxicity, tumor grade and the presence of bone metastasis and directly proportional to matching lesion findings between Octreoscan and computed tomography pre-PRRT and primary tumor and metastasis surgery.en
dc.rightsAtribución-NoComercial 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subject.meshIntestinal Neoplasms*
dc.subject.meshStomach Neoplasms*
dc.subject.meshProportional Hazards Models*
dc.subject.meshMiddle Aged*
dc.subject.meshNeoplasm Metastasis*
dc.subject.meshNeoplasm Grading*
dc.subject.meshOctreotide*
dc.subject.meshSurvival Rate*
dc.subject.meshHumans*
dc.subject.meshTreatment Outcome*
dc.subject.meshNeuroendocrine Tumors*
dc.subject.meshPancreatic Neoplasms*
dc.subject.meshAged*
dc.subject.meshPrognosis*
dc.titleEvaluation of Lu-177-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factorsen
dc.typeJournal Articlees
dc.authorsophosAbou Jokh Casas, E.;Pubul Núñez, V.;Anido-Herranz, U.;Del Carmen Mallón Araujo, M.;Del Carmen Pombo Pasín, M.;Garrido Pumar, M.;Cabezas Agrícola, J. M.;Cameselle-Teijeiro, J. M.;Hilal, A.;Ruibal Morell, Á
dc.identifier.doi10.3748/wjg.v26.i13.1513
dc.identifier.pmid32308351
dc.identifier.sophos38889
dc.issue.number13es
dc.journal.titleWORLD JOURNAL OF GASTROENTEROLOGYes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Anatomía Patolóxicaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Endocrinoloxíaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Medicina nucleares
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Oncoloxía médicaes
dc.page.initial1513es
dc.page.final1524 -es
dc.rights.accessRightsopenAccess
dc.subject.decspronóstico*
dc.subject.decsresultado del tratamiento*
dc.subject.decsneoplasias gástricas*
dc.subject.decstasa de supervivencia*
dc.subject.decsneoplasias intestinales*
dc.subject.decstumores neuroendocrinos*
dc.subject.decsmediana edad*
dc.subject.decsneoplasias pancreáticas*
dc.subject.decsmetástasis neoplásica*
dc.subject.decsanciano*
dc.subject.decsoctreótido*
dc.subject.decshumanos*
dc.subject.decsgradación neoplásica*
dc.subject.decsmodelos de riesgos proporcionales*
dc.subject.keywordCHUSes
dc.typefidesArtículo Originales
dc.typesophosArtículo Originales
dc.volume.number26es


Files in this item

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial 4.0 Internacional
Except where otherwise noted, this item's license is described as Atribución-NoComercial 4.0 Internacional